Allogenic human liver stem cell therapy - Unicyte AG
Alternative Names: Allogeneic adult liver-derived stem cells; Allogeneic human adult liver-derived stem cells; HLSC-001Latest Information Update: 03 Nov 2022
At a glance
- Originator Unicyte AG
- Class Hepatoprotectants; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Inborn urea cycle disorders
Most Recent Events
- 19 Sep 2022 Phase-II clinical trials in Inborn urea cycle disorders (In infants, In children, In neonates) in France (Intrahepatic) (EudraCT2022-000933-18; 700356871)
- 05 Mar 2012 Allogenic human liver stem cells - Unicyte AG receives Orphan Drug status for Inborn urea cycle disorders, Ornithine carbamoyltransferase deficiency disease and Inborn error metabolic disorders in European Union (EMA website, September 2022)